Trending Now
BioCardia (NASDAQ:BCDA) Receives Positive Recommendation To Continue Piboatl CardiAMP™ Heart Failure...
BioCardia (NASDAQ:BCDA) has announced the completion of its pre-specified data review for its third phase pivotal CardiAMP™ Heart Failure Trial. The independent...
DIH Holding US, Inc. (DHAI): Pioneering Rehabilitation with Cutting-Edge Technology
Let’s talk about something truly inspiring: the future of rehabilitation. On December 23, 2024, DIH Holding US, Inc. (NASDAQ: DHAI) announced...
Predictive Oncology Inc. (Nasdaq: POAI): A Transformative Acquisition by Renovaro Inc.
The biotechnological domain is currently abuzz with developments surrounding the acquisition of Predictive Oncology Inc. (Nasdaq: POAI) by Renovaro Inc. (Nasdaq: RENB)....
Popular News
Palisade Bio Inc (NASDAQ: PALI) Commences Dosing Of Patients In Phase...
Palisade Bio Inc (NASDAQ: PALI) has announced the dosing of the first patient in the third phase LB1148 assessment to accelerate bowel function restoration...
MAKE IT MODERN
LATEST REVIEWS
The GBT Foundation Announces the Submission of Applications for New Grants
The GBT foundation recently issued other organizations a chance to submit their applications for its latest sickle cell program. The program provides a call...
MAKE IT MODERN
PERFORMANCE TRAINING
Adverum Biotechnologies Inc (NASDAQ: ADVM) Completes Investigational New Drug Amendment for Start Phase 2...
Adverum Biotechnologies Inc (NASDAQ: ADVM) has announced the completion of its Investigational New Drug (IND) amendment with the US FDA and is planning to...
Onconova Therapeutics Inc. (NASDAQ: ONTX) Releases Safety And Efficacy Data of Rigosertib-Nivolumab Combination
Onconova Therapeutics Inc. (NASDAQ: ONTX) has releases interim efficacy and safety data from the investigator-initiated Phase 1/2, a study of oral rigosertib combination with...
Porch Group, Inc. (PRCH): Strong Q3 Performance Drives 55% Stock Surge Amid Strategic Wins...
Porch Group, Inc. (NASDAQ: PRCH), a comprehensive homeowners insurance and vertical software platform, experienced a remarkable 55.36% increase in its stock price,...
Artelo Biosciences Inc (NASDAQ:ARTL) Posts Net Loss Of $951,395 In Q3 2020
Artelo Biosciences Inc (NASDAQ:ARTL) widened net loss by 175.80% to $951,395 in Q3 2020. Its operating expenses related to R&D, administrative and general expenses...
Pfizer’s (NYSE: PFE) Ponsegromab Shows Promise in Fighting Cancer Cachexia
Pfizer (NYSE: PFE) recently announced positive results from a midstage trial of their experimental drug, ponsegromab, designed to treat cancer cachexia, a...
MAKE IT MODERN
